Oxurion NV and ThromboGenics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Oxurion NV and ThromboGenics Inc. - overview
Established
1991
Location
Leuven, -, Belgium
Primary Industry
Biotechnology
About
Based Leuven, Belgium, and founded 1991, Oxurion NV and ThromboGenics Inc. is a biopharmaceutical company developing ophthalmic therapies for diseases affecting the back of the eye. Oxurion is listed on Euronext Brussels under the symbol OXUR. The company employs 56 people worldwide.
The company develops therapies for better vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (wet AMD) and retinal vein occlusion (RVO). The company also offers JETREA® (ocriplasmin), pharmacological treatment indicated for symptomatic vitreomacular adhesion and vitreomacular traction (sVMA/ VMT). Oxurion NV and ThromboGenics Inc. will use the funding to building a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics.
Current Investors
Kreos Capital, Pontifax Venture Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Optometrists & Opticians Products and Services
Website
www.oxurion.com
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.